The pace at which you eat matters, too
In the ACHIEVE-3 Phase 3 trial, orforglipron was superior to oral semaglutide on both HbA1c reduction (approximately 2.2 vs 1.4 percentage points) and weight loss
When extrapolated to human-equivalent dosing using standard conversion factors, this translates to approximately 0.050.8 mg/kg
Food and Drug Administration (FDA) approval in May 2022 for type 2 diabetes, November 2023 for chronic weight management, and December 2024 for obstructive sleep apnea, marking it as the first approved therapy for this indication
Exercise and lifestyle strategies for brain health [12:30]
Some individuals have faced challenges like initial skin irritation, slow progress, or even unrealistic expectations